Atlas.
Sign inStart free trial
ALLONASDAQ · US

Allogene Therapeutics, Inc.

Technology · Biological Products, (No Diagnostic Substances)

TechnologyBiological Products, (No Diagnostic Substances)
CEO
David Chang, M.D., Ph.D.
Founded
—
IPO Date
—
HQ
South San Francisco, CA, United States
Exchange
NASDAQ
Employees
n.a.

Share Price Performance

$2.11 ▲ 56.3%
Last (1 Jul 2026) · $2
Period High · $3.06
Period Low · $0.00
52W: $2.11 – $3.06

Key Metrics

Share Price
$2.11
+1.4% today
Market Cap
$474M
P / E
—
EV / Revenue
—
Revenue Growth
—
year-on-year
Gross Margin
—
Enterprise Value
$422M
52W High
$3.06
52W Low
$0.00
Avg Volume
10.7M
daily

Sources: SEC filings · Market data as of Jul 6, 2026

Shareholders' Structure
13 known institutional holders·$110M total on record·2026-Q1
BlackRock, Inc.
8.5%·$47M
State Street Corp
3.9%·$21M
Price T Rowe Associates Inc
2.4%·$13,130
Geode Capital Management, LLC
1.8%·$10M
Goldman Sachs Group Inc
1.2%·$7M
Renaissance Technologies LLC
1.0%·$5M
Bank Of America Corp
0.9%·$5M
Fmr LLC
0.7%·$4M
Jpmorgan Chase & Co
0.6%·$3M
Northern Trust Corp
0.6%·$3M
Dimensional Fund Advisors LP
0.5%·$3M
Invesco Ltd.
0.3%·$2M
Point72 Asset Management, L.P.
0.1%·$540,057
Free Float
77.4%

Sources: SEC filings

Notes: % shown as share of total shares outstanding · Free float = shares outstanding minus all known 13F institutional holdings

What Atlas covers for Allogene Therapeutics, Inc.
OverviewAllogene Therapeutics, Inc. share price history (10 years), key market statistics, and institutional shareholder structure from SEC 13F-HR filings.Business ModelHow Allogene Therapeutics, Inc. generates revenue — product and service segments, geographic breakdown, key operating metrics, and 10-year business evolution sourced from SEC filings.FinancialsAllogene Therapeutics, Inc.'s complete financial history — 10 years of annual revenue, gross margins, operating income, net income, EPS, and free cash flow from SEC filings, plus 12 quarters of quarterly results.Management QualityAllogene Therapeutics, Inc. executive team profiles, insider buying and selling from SEC Form 4, earnings call transcripts, and a track record of guidance delivery vs actual results.Risk FactorsAllogene Therapeutics, Inc.'s annual risk disclosures from SEC filings — full text, 5-year evolution showing how risks have shifted, and year-on-year delta highlighting new and removed risks.NewsAI-synthesised news digest for Allogene Therapeutics, Inc., updated regularly with key developments, earnings updates, product announcements, and material company events.SentimentInvestor sentiment for Allogene Therapeutics, Inc. aggregated from X.com, Reddit, and Hacker News — discussion themes, Bull and Bear signals, and community analysis.Valuation & PeersAllogene Therapeutics, Inc. valuation multiples — P/E, EV/Revenue, EV/EBITDA — compared against a curated set of industry peers using live data from SEC filings. Custom peer selection available.DCF BuilderBuild a discounted cash flow model for Allogene Therapeutics, Inc. with 10 years of pre-filled revenue, margins, and cash flow data from SEC filings. Adjust growth rates, WACC, and terminal assumptions.Atlas AnalysisAtlas AI research synthesis for Allogene Therapeutics, Inc. — business model, financial health, management quality, risk profile, and institutional ownership, grounded exclusively in SEC filings.

Unlock the full analysis

9-tab institutional research sourced directly from SEC filings. No tips, no scores — the same process professional investors use.

7-day free trial · Plus & Pro · No charge during trial